A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

Phase 2

Oncotherapeutics

Venetoclax